bluebird bio, Inc. (NASDAQ:BLUE) Receives Average Rating of “Hold” from Analysts

bluebird bio, Inc. (NASDAQ:BLUE) has received an average recommendation of “Hold” from the nine brokerages that are presently covering the firm, MarketBeat reports. Two investment analysts have rated the stock with a sell recommendation, five have issued a hold recommendation and two have assigned a buy recommendation to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $49.14.

A number of analysts have recently commented on the company. StockNews.com initiated coverage on bluebird bio in a research note on Friday, December 20th. They issued a “sell” rating for the company. Bank of America lowered shares of bluebird bio from a “buy” rating to a “neutral” rating and cut their target price for the stock from $60.00 to $10.00 in a report on Friday, November 15th. Royal Bank of Canada reissued a “sector perform” rating and issued a $80.00 price target on shares of bluebird bio in a report on Friday, November 15th. JPMorgan Chase & Co. downgraded bluebird bio from a “neutral” rating to an “underweight” rating in a research note on Friday, November 15th. Finally, Wells Fargo & Company decreased their target price on bluebird bio from $60.00 to $40.00 and set an “equal weight” rating for the company in a research note on Wednesday, September 25th.

Institutional Trading of bluebird bio

A number of institutional investors have recently modified their holdings of the company. AQR Capital Management LLC grew its holdings in shares of bluebird bio by 315.3% during the second quarter. AQR Capital Management LLC now owns 1,334,519 shares of the biotechnology company’s stock worth $1,223,000 after buying an additional 1,013,144 shares in the last quarter. BNP Paribas Financial Markets grew its stake in shares of bluebird bio by 2,270.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 371,224 shares of the biotechnology company’s stock worth $193,000 after acquiring an additional 355,562 shares in the last quarter. FMR LLC grew its stake in shares of bluebird bio by 8.1% during the 3rd quarter. FMR LLC now owns 2,481,965 shares of the biotechnology company’s stock worth $1,289,000 after acquiring an additional 186,903 shares in the last quarter. Barclays PLC raised its holdings in shares of bluebird bio by 273.7% in the third quarter. Barclays PLC now owns 252,062 shares of the biotechnology company’s stock valued at $130,000 after purchasing an additional 184,605 shares during the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of bluebird bio by 3.7% in the third quarter. Geode Capital Management LLC now owns 4,683,042 shares of the biotechnology company’s stock worth $2,433,000 after purchasing an additional 166,771 shares in the last quarter. 87.43% of the stock is currently owned by institutional investors.

bluebird bio Trading Down 0.4 %

NASDAQ BLUE opened at $8.26 on Friday. bluebird bio has a 12 month low of $5.80 and a 12 month high of $38.40. The stock has a 50-day simple moving average of $8.11 and a 200 day simple moving average of $12.30. The company has a current ratio of 0.51, a quick ratio of 0.33 and a debt-to-equity ratio of 0.37. The company has a market capitalization of $80.29 million, a PE ratio of -0.22 and a beta of 0.68.

About bluebird bio

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.